Cheryl R. Blanchard - Mar 11, 2022 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Role
President, CEO, Director, Director
Signature
/s/ Cheryl R. Blanchard
Stock symbol
ANIK
Transactions as of
Mar 11, 2022
Transactions value $
$0
Form type
4
Date filed
3/15/2022, 05:00 PM
Previous filing
Mar 11, 2022
Next filing
Apr 28, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANIK Restricted Stock Unit Award $0 +90.2K $0.00 90.2K Mar 11, 2022 Common Stock 90.2K $0.00 Direct F1
transaction ANIK Stock Option (Right to Buy) Award $0 +209K $0.00 209K Mar 11, 2022 Common Stock 209K $28.14 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each RSU represents the contingent right to receive one share of the Company's common stock. The RSUs vest in three equal annual installments beginning March 11, 2023.
F2 Represents a 10% premium above the closing price of Anika's common stock on the date of grant.
F3 The premium priced stock options vest in three equal annual installments beginning on March 11, 2023.